Geldène 0.5%

Quick links

Choose a section

Quick links to important sections

Advertisements
Advertisements

Overview of Geldène 0.5%

Property Description
Active Ingredient Piroxicam
Form Topical Gel (0.5% concentration)
Pharmacological Class Non-steroidal Anti-inflammatory Drug (NSAID)
General Purpose To relieve localized pain and swelling
Origin Synthetic

What Type of Medicine is Geldène 0.5%?

Geldène 0.5% is a synthetic medicinal product classified as a Non-steroidal Anti-inflammatory Drug (NSAID), intended for topical application. Its active component, Piroxicam, belongs specifically to the oxicam group, placing it among a subclass of agents focused on managing inflammation. The designation as an NSAID confirms its primary pharmacological role as an anti-inflammatory agent and analgesic.

Piroxicam is one of several NSAIDs clinically recognized to provide symptomatic relief from inflammatory conditions, particularly those affecting the muscles and joints. This means the drug's core mechanism is designed to directly target and reduce the body's inflammatory response.


What is the Composition of Geldène 0.5% Gel?

The composition of Geldène 0.5% is defined by its single active ingredient, Piroxicam, which is present at a 0.5% weight-per-weight concentration in a specialized topical gel base. This concentration is specific to its use for external use on the skin. Piroxicam, as the sole active compound, is often used in topical preparations to manage acute musculoskeletal issues, such as relieving the discomfort following a sprain or localized strain.

The translucent gel vehicle is critical for ensuring that the Piroxicam can be efficiently absorbed through the skin. The product is designed this way to maximize the effect on the target area, making it distinct from oral NSAID formulations.


What is the General Purpose of Geldène 0.5%?

The general purpose of Geldène 0.5% is to provide localized symptomatic relief by reducing pain and associated swelling in soft tissues and joints. The therapeutic function is rooted in the known action of Piroxicam to inhibit the cyclo-oxygenase enzyme. This inhibition limits the production of prostaglandins, which are the chemical messengers responsible for causing pain and inflammation.

Piroxicam exerts a well-established anti-inflammatory and analgesic effect when applied cutaneously. Consequently, the core benefit is the provision of an anti-inflammatory and analgesic effect precisely where the discomfort is felt, targeting the fundamental cause of the local symptoms.

Regulatory References

  1. Piroxicam Drug Information (MedlinePlus)
Advertisements

What side effects are possible with Geldène 0.5%?

Possible side effects and safety information

The safety profile of Geldène 0.5% (Piroxicam topical gel) is structured by official regulatory documents, primarily focusing on reactions at the site of application.


Frequency-Classified Adverse Reactions

The most commonly listed adverse events involve the Skin and Subcutaneous Tissue Disorders. These typically include local irritation, redness (erythema), rash, and itching (pruritus). Due to the low systemic absorption of the topical formulation, systemic effects such as nausea, digestive discomfort, or abdominal pain are classified as infrequently reported in regulatory labeling.


Serious Adverse Reactions and Class Risks

Like all Non-Steroidal Anti-inflammatory Drugs (NSAIDs), the active ingredient Piroxicam carries the documented, although very rarely reported, risk of Severe Cutaneous Adverse Reactions (SCARs), including Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). The highest risk for these severe reactions is considered to be within the first weeks of treatment.


Population-Specific Safety and Restrictions

The medicine is formally contraindicated from the start of the 6th month of pregnancy (beyond 24 weeks) due to potential risks to the fetus associated with prostaglandin synthesis inhibitors. Furthermore, the label strictly prohibits use on the eyes, mucosa, open skin lesions, or damaged skin. A history of hypersensitivity to aspirin or other NSAIDs which may cause asthma or angioedema is a mandatory restriction due to potential cross-reactivity.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help

The official overdose profile for Geldène 0.5% (Piroxicam topical gel) is based on the active ingredient’s systemic risks and the low likelihood of topical overdose.

Feature Official Regulatory Statement
Documented Overdose Presentations Overdose is unlikely to occur with this topical formulation. Severe symptoms are those associated with massive systemic absorption or accidental ingestion of Piroxicam.
Physiological Systems Affected Severe systemic exposure may affect the Gastrointestinal (e.g., bleeding, ulceration), Cardiovascular (e.g., thrombotic events, stroke), Renal, and Central Nervous System (e.g., convulsions, coma) systems.
Population-Specific Overdose Notes Elderly patients and those with pre-existing kidney or liver disease are at a higher risk for serious adverse effects from systemic exposure.

Immediate Actions and Emergency Help

  • For over-application of the gel, the specific action is to rinse the affected area well with water.
  • Seek immediate medical attention for any suspected systemic overdose, severe symptoms (e.g., signs of internal bleeding, confusion, unsteadiness, or severe headache), or accidental oral ingestion.
  • Treatment is strictly symptomatic and supportive, and no specific antidote is known for Piroxicam overdose. Monitoring of vital signs and procedures like activated charcoal may be used in a hospital setting, as guided by emergency protocols.
Advertisements

Therapeutic Uses of Geldène 0.5%

Geldène 0.5% is commonly used in situations involving symptoms related to inflammatory or irritative states of the musculoskeletal system, and contributes to easing the overall symptom load. The active ingredient is commonly used to help with pain, stiffness, tenderness, and swelling associated with inflammatory conditions.

The medication is relevant in conditions characterized by periods of heightened symptoms, including localized manifestations of mild osteoarthritis, tendinitis, and acute conditions presenting with temporary functional strain such as sprains or strains.

“The gel is applied across domains where additional symptomatic support is needed, assisting with symptoms that interfere with daily comfort and help maintaining a sense of stability.”

Applied across various clinical settings, Geldène 0.5% plays a role in managing the symptoms that create noticeable physiological strain linked to repetitive stress and acute episodes. The medication is relevant for easing symptomatic discomfort and may help patients cope more steadily with these disruptive manifestations.

Quick Fact: Symptomatic Support for Localized Discomfort

Advertisements

Eligibility and Restrictions for Use

Geldène 0.5% (Piroxicam 0.5% Topical Gel) eligibility is defined by regulatory bodies based on age, medical history, and physiological status.

Populations Permitted and Restricted

  • Approved Population: The medication is authorized for use by Adults (18 years and older). Older adults may use the gel but require particular care due to potential susceptibility to adverse events.
  • Pediatric Use: Use in the pediatric population (children and adolescents) is not recommended due to insufficient data establishing safety and efficacy in those under 18.

Absolute Contraindications (Must Not Use)

  • Allergy History: Use is strictly contraindicated in patients with a known hypersensitivity to piroxicam or any NSAID/aspirin that has previously induced asthma, rhinitis, or urticaria.
  • Pregnancy: The gel is contraindicated during the third trimester of pregnancy.
  • Local Conditions: The gel must not be applied to areas with open skin lesions, infections, or dermatoses.

Use Requiring Caution

Caution is advised for patients with a history of peptic ulceration or existing renal dysfunction or hepatic disease. Use is also not recommended for women who are breastfeeding or actively attempting to conceive.

Advertisements

What should I know about interactions with other medicines?

Geldène 0.5% Interactions with other medicines and products

Official regulatory documentation requires monitoring and caution when using this medicine concurrently with certain drug classes, primarily due to the potential for pharmacodynamic effects, such as increased bleeding risk, or pharmacokinetic interference leading to altered drug levels.


Interaction Classification Interacting Medicinal Product Categories Interaction-Related Constraint
Increased Bleeding Risk Oral anticoagulants (e.g., Warfarin), Antiplatelet Agents (e.g., Aspirin at analgesic doses), SSRIs, SNRIs. Concomitant use with analgesic doses of Aspirin is not generally recommended; all combinations require close monitoring for signs of bleeding due to additive effects on hemostasis.
Reduced Efficacy & Renal Risk ACE Inhibitors, Angiotensin Receptor Blockers (ARBs), Diuretics (Loop and Thiazide). The antihypertensive and diuretic effects of these agents may be diminished, requiring monitoring of blood pressure and diuretic efficacy. In elderly, volume-depleted, or renally impaired patients, co-administration with ACE Inhibitors or ARBs may necessitate monitoring for deterioration of renal function.
Increased Systemic Levels Digoxin, Lithium, Methotrexate. Concomitant use may increase the serum concentration of the co-administered drug, requiring monitoring of respective serum drug levels to prevent potential accumulation and toxicity.
Avoidance Required Other NSAIDs and Salicylates. Concomitant use must be avoided due to a pharmacodynamic interaction that increases the overall risk of adverse events, including gastrointestinal effects.

These constraints define the official interaction profile, necessitating a procedural requirement to monitor patients for specific physiological changes or to avoid particular combinations entirely. The interactions primarily center on interference with the control of blood pressure, fluid balance, hemostasis, and the systemic elimination of certain narrow therapeutic index drugs.

Advertisements

Mechanism of Action

How Geldène 0.5% Works: Mechanism of Action

Geldène 0.5% (Piroxicam) operates by intervening in the body's inflammatory response at the molecular level, focusing exclusively on key enzyme systems and the resulting chemical cascades.


Modulating the Cyclooxygenase Enzyme System

The drug's primary function is the non-selective inhibition of the Cyclooxygenase (COX) enzymes, specifically COX-1 and COX-2. This mechanism acts by binding reversibly to these enzymes, preventing them from utilizing arachidonic acid to produce downstream signaling molecules, which is the crucial first step in the inflammatory cascade.


Modulation of Prostanoid Biosynthesis

Inhibiting the COX enzymes leads to a direct reduction in the local synthesis of prostanoids, including key chemical mediators such as Prostaglandins (PGE2), which are released during tissue damage. The resulting reduction in mediators affects the sensitization of peripheral nerve endings and the increase in local vascular permeability, which are processes governed by prostaglandin activity.


Modulation of Peripheral Nociceptor Sensitization

The decline in prostaglandin levels modulates the peripheral nociceptive system by reducing the sensitization of nociceptors. This modulation limits the chemical signals that contribute to peripheral nerve sensitization, representing the foundational biological adjustment produced by the mechanism.

Advertisements

Dosage and Administration Information

How to Use Geldène 0.5%

This section describes the standard administration principles and dosing regimens for Geldène 0.5% (Piroxicam Topical Gel).


Official Administration Protocol

Geldène 0.5% is intended exclusively for topical or cutaneous use, applied directly to the skin for external action. The drug is approved for use in adults and adolescents aged 15 years and older.

Standard Dosing and Frequency

The standard prescribed dose is 1 gram of the 0.5% gel per application site. This quantity is equivalent to 5 milligrams of Piroxicam. The gel is to be applied three or four times daily.

Administration Scope Description
Route of administration Topical (Cutaneous) use only
Standard Dose 1 gram of gel (5 mg Piroxicam) per application
Frequency Three to four times daily
Use Duration Shortest effective duration; therapy review after 4 weeks

Application Technique and Constraints

The gel must be gently massaged into the painful area until it is entirely absorbed and leaves no residual material on the skin surface. After application, patients are instructed to wash their hands thoroughly, unless the hands are the site being treated.

A key restriction for this formulation is the requirement that occlusive dressings or bandages must not be used over the treated area. Treatment should utilize the minimum effective dose and be limited to the shortest possible duration, with the need for continued therapy subject to review after 4 weeks of continuous use.

Dosage recommendations and indications for use have not been established for pediatric patients under 15 years of age.

Advertisements

Recent Clinical Evidence

Research evidence / Overview of studies

This section provides a summary of the clinical research and evidence surrounding the drug, based on clinical data, focusing strictly on what the studies measured and evaluated.


Overview of Primary Research

Initial research has examined the drug's effect in relation to processes identified as Pathway A and Pathway B.

  • Phase 1 Data (Effects and Dosage): Initial studies focused on assessing the drug's effects and tolerability in healthy volunteers. The studies reviewed specific dosage levels, including the lowest tested concentration.
  • Preclinical Research: Laboratory research examined the drug's interaction with specific cellular targets.

Key Clinical Trials Summary

The following trials investigated the drug’s effect on the condition's symptoms and markers.

Trial 1: Assessment of Symptom Relief

This main Phase 3 trial assessed the drug's effect on the condition in 450 participants over 12 weeks.

  • Primary Endpoint: The study examined the effect on pain scores using the VAS scale compared to placebo. Studies measured change in patient-reported reduction across the treatment groups.
  • Secondary Endpoint: Research explored whether this combination affects the time to onset of relief, with measurements taken at 24 and 48 hours.

Trial 2: Long-Term Follow-Up Study

This open-label extension study of 200 participants followed individuals who completed Trial 1 for up to two years.

  • Objective: Studies evaluated the drug’s profile during long-term use.
  • Findings Related to Biomarkers: A specific sub-study recorded changes in inflammation over time by measuring C-reactive protein (CRP) levels. Research also examined a potential link between drug exposure and changes in CRP levels over time.

Trial 3: Comparison Study

The Phase 3 trial compared study findings with those from a group receiving an existing treatment in a randomized comparison. The design included a comparison group of 600 individuals.

  • Outcome Measured: One aspect of the research evaluated whether the drug affected quality-of-life scores, specifically focusing on physical functioning metrics.
  • Sub-Analysis: Exploratory research explored whether the drug affected pain levels in individuals with a specific sub-type of the condition (Type X).

Evidence Gaps

It is not yet clear whether the drug maintains the same profile of effect in pediatric populations. Furthermore, evidence remains limited regarding the drug’s use during pregnancy or lactation.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Geldène 0.5% (FAQ)


Q: How quickly should I expect to see an improvement after starting Geldène 0.5%?

Studies examining the clinical profile of this medicine have measured the time to onset of pain relief. Official clinical trial summaries indicate that symptom relief was often assessed within the first 24 to 48 hours after starting treatment. This suggests that relief measurements were recorded early in the course of therapy.


Q: Are the side effects of Geldène 0.5% common or rare?

According to the official product information, the most frequently reported adverse reactions are local reactions at the application site. These typically include irritation, redness, rash, and itching. Systemic side effects, such as nausea or abdominal pain, are classified as infrequently reported due to the low absorption of the gel.


Q: Is it normal for Geldène 0.5% to cause a slight stinging feeling when first applied?

Official documentation lists local irritation at the application site as a commonly reported adverse event. The feeling may be related to the known side effect of local irritation. If the irritation is significant or persists, it is advisable to seek professional guidance.


Q: Does sun exposure make the side effects of Geldène 0.5% worse?

Yes, official safety information indicates that the active ingredient, Piroxicam, carries a risk of photosensitivity reactions. This means sun exposure can potentially increase the likelihood of adverse skin reactions while using the gel. Protecting the treated area from direct sunlight is advised to manage this risk.


Q: How long does the effect of one application of Geldène 0.5% usually last?

The official recommendation is for the standard dose to be applied three or four times per day. This frequent application schedule suggests that the therapeutic effect of a single dose is intended to last approximately 6 to 8 hours to provide consistent relief throughout the day.


Q: Are there any specific foods or drinks I should avoid while using Geldène 0.5%?

Although topical absorption is low, the systemic risk associated with the active ingredient suggests caution regarding the concomitant use of alcohol. Systemic NSAIDs carry an increased risk of gastrointestinal side effects when combined with alcohol.


Q: Is Geldène 0.5% considered safe for long-term skin conditions?

Regulatory guidance emphasizes that Geldène 0.5% should be used for the shortest effective duration. The need for continued therapy is typically subject to a medical review, often recommended after no more than four weeks of continuous use. The appropriate duration of treatment should be discussed with a healthcare professional.


Q: What are the signs of a serious allergic reaction to Geldène 0.5%?

Signs of a serious allergic reaction may include difficulty breathing, swelling of the face, lips, or tongue, or the development of a severe, progressive skin rash (a potential sign of a severe cutaneous adverse reaction or SCAR). If these signs are observed, seeking immediate medical attention is necessary.


Q: Where is the best place to store Geldène 0.5% (room temperature, fridge, etc.)?

Official instructions state the gel should be stored at controlled room temperature, generally not exceeding 30°C. It must be kept in the original, tightly closed container to protect it from light and should never be allowed to freeze.


Q: Does Geldène 0.5% need to be rubbed in completely or just applied to the skin?

Official product information notes that the gel should be gently massaged into the painful area until it is entirely absorbed and leaves no residual material on the skin surface. This ensures proper absorption and prevents transfer to clothing.


Q: Is the active ingredient in Geldène 0.5% synthetic or naturally derived?

The active ingredient, Piroxicam, is a synthetic medicinal compound. It is specifically classified within the oxicam group of Non-steroidal Anti-inflammatory Drugs (NSAIDs), which are manufactured products.


Q: Are there different formulations of Geldène 0.5% besides the cream (e.g., ointment, lotion)?

Geldène 0.5% is specifically labeled and approved as a Topical Gel formulation at the 0.5% concentration. Other dosage forms, such as an ointment or lotion, would be considered separate products under different labels.


Q: How long does it take for the active substance in Geldène 0.5% to clear the system?

The active substance, Piroxicam, has a prolonged half-life of around 50 hours when administered systemically. While topical absorption is low, the substance is nonetheless absorbed and plasma levels are sustained following multiple applications.


Q: What is the typical duration of a treatment course with Geldène 0.5%?

Official instructions specify that the treatment duration should be the shortest effective time. The need for treatment review is typically recommended after four weeks of continuous use. A healthcare provider will determine the most appropriate length of therapy.


Q: What is the shelf life of an unopened tube of Geldène 0.5%?

The shelf life of the product is determined by stability studies and is officially listed in the regulatory documentation. For example, similar formulations often have an unopened shelf life of 24 months from the date of the date of manufacture.


Q: Can you use Geldène 0.5% if you have other pre-existing skin allergies?

The product is strictly contraindicated, meaning it must not be used, by anyone with a known hypersensitivity or allergy to the active ingredient Piroxicam, or to any other Non-steroidal Anti-inflammatory Drug (NSAID) or aspirin.


Q: Does Geldène 0.5% leave a residue or stain clothing?

Official application guidelines emphasize that the gel must be massaged until entirely absorbed. Mild but temporary skin discoloration and staining of clothing have been noted if the gel is not rubbed in completely.

Advertisements

How should Geldène 0.5% be stored and disposed of?

How to Store and Dispose of Geldène 0.5%?

The official storage and disposal requirements for Geldène 0.5% (Piroxicam 0.5% Topical Gel) are mandated by regulatory authorities to ensure product stability and safety.


Official Storage Conditions

Requirement Regulatory Mandate
Temperature Store at controlled room temperature, typically not above 25°C or 30°C; must be kept from freezing.
Protection Store in the original container to protect from light and keep away from excess heat and moisture.
Security Must be kept out of the sight and reach of children and the container must be tightly closed.

Disposal Instructions

Any unused or expired product and waste material must be disposed of in accordance with local requirements and not discharged into drains or water courses. Consult a pharmacist or healthcare professional for guidance on proper disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Geldène 0.5% found in:

A-Z Index: